BDX insider transaction filings
BECTON DICKINSON & CO — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-03. Screen BDX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 6 filings by 4 insiders — 8,005 shares, $1,423,580 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: sale of 4,152 shares @ $185.00 ($768,120) by Polen Thomas E Jr, filed 2026-08-14.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Polen Thomas E Jr — Chairman, CEO and President, Director | 1 | — | 1 leg · 4,152 sh · $768,120 | 3 |
| Goette Roland — EVP and President, EMEA | 1 | — | 1 leg · 2,438 sh · $440,888 | — |
| Garrison Michael David — EVP & Pres Med.Essntl&BioPharm | 1 | — | 1 leg · 1,100 sh · $160,226 | — |
| Feld Michael — EVP, Chief Revenue Officer | 4 | — | 3 legs · 315 sh · $54,346 | 1 |
| Muhsin Bilal — EVP & President Connected Care | 1 | — | — | 2 |
| Byington Carrie L — Director | 1 | — | — | 1 |
| Huffines Robert Luther — Director | 1 | — | — | 1 |
| Roque Vitor — EVP & Chief Financial Officer | 1 | — | — | 1 |
Recent Form 4 filings — BECTON DICKINSON & CO
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Roque Vitor — EVP & Chief Financial Officer | Tax withholding (F): 190 @ $0 | EDGAR |
| 2026-08-27 | 4 | Feld Michael — EVP, Chief Revenue Officer | Sale (S): 165 @ $188.49 | EDGAR |
| 2026-08-24 | 4 | Feld Michael — EVP, Chief Revenue Officer | Tax withholding (F): 1,049 @ $0 | EDGAR |
| 2026-08-14 | 4 | Polen Thomas E Jr — Chairman, CEO and President, Director | Option exercise (M): 43,278 @ $167.25 · Disposition to issuer (D): 39,126 @ $185 · Sale (S): 4,152 @ $185 · Option exercise (M): 43,278 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Goette Roland — EVP and President, EMEA | Sale (S): 2,438 @ $180.84 | EDGAR |
| 2026-08-06 | 4 | Byington Carrie L — Director | Grant/award (A): 94 (derivative) @ $165.62 | EDGAR |
| 2026-08-06 | 4 | Huffines Robert Luther — Director | Grant/award (A): 189 (derivative) @ $165.62 | EDGAR |
| 2026-07-28 | 4 | Feld Michael — EVP, Chief Revenue Officer | Sale (S): 75 @ $157.13 | EDGAR |
| 2026-07-06 | 4 | Muhsin Bilal — EVP & President Connected Care | Grant/award (A): 14,342 @ $0 · Tax withholding (F): 1,935 @ $0 | EDGAR |
| 2026-06-26 | 4 | Feld Michael — EVP, Chief Revenue Officer | Sale (S): 75 @ $152.80 | EDGAR |
| 2026-06-25 | 4 | Garrison Michael David — EVP & Pres Med.Essntl&BioPharm | Sale (S): 1,100 @ $145.66 | EDGAR |
| 2026-06-11 | 4 | Garrison Michael David — EVP & Pres Med.Essntl&BioPharm | Sale (S): 1,100 @ $151.48 | EDGAR |
| 2026-06-03 | 4 | Polen Thomas E Jr — Chairman, CEO and President, Director | Option exercise (M): 20,209 @ $126.16 · Disposition to issuer (D): 17,445 @ $146.15 · Sale (S): 2,764 @ $146.35 · Option exercise (M): 20,209 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Menziuso Peter — EVP and President, BDI | Grant/award (A): 14,258 @ $0 | EDGAR |
| 2026-05-27 | 4 | Feld Michael — EVP, Chief Revenue Officer | Sale (S): 75 @ $147.35 | EDGAR |
| 2026-05-08 | 4 | Huffines Robert Luther — Director | Grant/award (A): 210 (derivative) @ $149.04 | EDGAR |
| 2026-05-08 | 4 | Byington Carrie L — Director | Grant/award (A): 105 (derivative) @ $149.04 | EDGAR |
| 2026-05-08 | 4 | Roque Vitor — EVP & Chief Financial Officer | Grant/award (A): 1,721 @ $0 | EDGAR |
| 2026-04-28 | 4 | Feld Michael — EVP, Chief Revenue Officer | Sale (S): 74 @ $151.94 | EDGAR |
| 2026-04-06 | 4 | Neal Shana Carol — EVP and Chief People Officer | Tax withholding (F): 1,146 @ $0 | EDGAR |
| 2026-03-27 | 4 | Feld Michael — EVP, Chief Revenue Officer | Sale (S): 75 @ $156.83 | EDGAR |
| 2026-03-17 | 4 | Minnix Lanesha — EVP and General Counsel | Grant/award (A): 7,492 @ $0 | EDGAR |
| 2026-03-04 | 4 | Roque Vitor — Interim CFO | Grant/award (A): 931 @ $0 | EDGAR |
| 2026-03-04 | 4 | Spikner Pamela L. — SVP Controller & CAO | Grant/award (A): 931 @ $0 | EDGAR |
| 2026-02-27 | 4 | Feld Michael — EVP, Chief Revenue Officer | Sale (S): 75 @ $181.84 | EDGAR |
| 2026-02-18 | 4 | SCOTT BERTRAM L — Director | Sale (S): 953 @ $182.61 | EDGAR |
| 2026-02-05 | 4 | Huffines Robert Luther — Director | Grant/award (A): 100 (derivative) @ $201.91 | EDGAR |
| 2026-02-05 | 4 | Byington Carrie L — Director | Grant/award (A): 30 (derivative) @ $201.91 | EDGAR |
| 2026-02-05 | 4 | Jones Christopher Ian Montague — Director | Grant/award (A): 272 (derivative) @ $201.91 | EDGAR |
| 2026-01-29 | 4 | Henderson Jeffrey William — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | ECKERT R ANDREW — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | Byington Carrie L — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | HAYES GREGORY — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | Brown William M — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | Huffines Robert Luther — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | Jones Christopher Ian Montague — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | RING TIMOTHY M — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | SCOTT BERTRAM L — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | Waldstreicher Joanne — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-29 | 4 | Wright Jacqueline — Director | Grant/award (A): 1,098 @ $0 | EDGAR |
| 2026-01-28 | 4 | Feld Michael — EVP, CRO & Pres. Life Sciences | Sale (S): 75 @ $202.73 | EDGAR |
| 2026-01-23 | 4 | Spikner Pamela L. — SVP Controller & CAO | Tax withholding (F): 84 @ $0 | EDGAR |
| 2026-01-16 | 4 | Garrison Michael David — EVP & Pres Med.Essntl&BioPharm | Option exercise (M): 3,054 @ $167.91 · Disposition to issuer (D): 2,454 @ $209 · Sale (S): 600 @ $209 · Sale (S): 1,010 @ $206.54 · Option exercise (M): 3,054 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Shan David — EVP and Chief ISC Officer | Tax withholding (F): 44 @ $0 | EDGAR |
| 2025-12-29 | 4 | Feld Michael — EVP, CRO & Pres. Life Sciences | Sale (S): 74 @ $196.08 | EDGAR |
| 2025-12-17 | 4 | Garrison Michael David — EVP & Pres Med.Essntl&BioPharm | Sale (S): 629 @ $196.03 | EDGAR |
| 2025-12-02 | 4 | Feld Michael — EVP, CRO & Pres. Life Sciences | Sale (S): 75 @ $193.36 | EDGAR |
| 2025-12-02 | 4 | Wright Jacqueline — Director | Grant/award (A): 180 @ $0 | EDGAR |
| 2025-12-02 | 4 | Huffines Robert Luther — Director | Grant/award (A): 180 @ $0 | EDGAR |
| 2025-12-01 | 4 | Spikner Pamela L. — SVPController & Chief Acct Off | Grant/award (A): 1,234 @ $0 | EDGAR |
Recent 8-K events — BECTON DICKINSON & CO
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-05-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BDX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →